Pharmacologic basis of pantoprazole dosing

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 8, 2000, Pages 507-522

  Katz, Philip O ^a  

^a GRADUATE HOSPITAL   (United States)

Author keywords

Gastroesophageal reflux; Pantoprazole; Peptic ulcer; Proton pump

Indexed keywords

PANTOPRAZOLE; PROTON PUMP INHIBITOR;

DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; GASTROESOPHAGEAL REFLUX; HUMAN; PRIORITY JOURNAL; REVIEW; STOMACH PH;

EID: 0033843398     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)80033-8     Document Type: Article

References (70)

1. The discovery of iron pumps
2. Inhibition of the gastric acid pump
3. The site of acid secretion in the mammalian parietal cell
4. - conductances in the apical membrane from secreting oxyntic cells are concurrently inhibited by divalent cations
5. The parietal cell
6. Ion motive ATPases
7. Review article: The continuing development of proton pump inhibitors with particular reference to pantoprazole
8. The mechanism and structure of the gastric H,K-ATPase
9. The continuing development of gastric acid pump inhibitors
10. + ATPase
11. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione
12. Proton pump inhibitors
13. Rabeprazole: Pharmacokinetics in patients with stable, compensated cirrhosis
14. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates
15. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast
16. Setting the 'gold standards' in the management of gastroesophageal reflux disease
17. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter study
18. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis
19. Healing and relapse of severe peptic esophagitis after treatment with omeprazole
20. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis
21. Pharmacokinetics and drug interactions - Relevant factors for the choice of a drug
22. Proton pump inhibitory therapy: Then and now
23. Proton pump inhibitors: New drugs and indications
24. +-ATPase inhibitor with an improved pH stability
25. +-ATPase
26. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents
27. +-ATPase inhibitor pantoprazole after single intravenous administration
28. Pantoprazole heals erosive esophagitis (EE) more effectively and provides greater symptomatic relief than placebo or nizatidine in gastroesophageal reflux disease (GERD) patients
29. Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis
30. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-ellison syndrome
31. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects
32. A double-blind, randomized, crossover, doseresponse study of the effects of 10, 20, or 40 mg of oral pantoprazole taken once daily on intragastric pH in healthy adults
33. Dose-response of pantoprazole 20, 40 and 80 mg on 24-hour intragastric pH and serum gastrin in man
34. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects
35. Comparison of 24-h intragastric pH and 24-h gastrin profiles during therapy with the proton pump inhibitors pantoprazole and omeprazole
36. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole
37. Comparison of pantoprazole 20 mg twice daily with 40 mg once daily on intragastric pH in healthy volunteers
38. Morning and evening administration of pantoprazole: A study to compare the effect on 24-hour intragastric pH
39. Pharmacokinetics of the proton pump inhibitor pantoprazole in patients with severe renal impairment
40. Pantoprazole in the elderly: No doseadjustment
41. Pantoprazole in patients with varying degree of liver impairment in comparison to healthy controls
42. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose ranging study
43. BY 1023/SKandF 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions
44. +-ATPase inhibitor pantoprazole (BY1023/SKandF96022) interacts less with cytochrome P450 than omeprazole and lansoprazole
45. Different affinities of proton pump inhibitors to cytochrome P450 in man
46. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes
47. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction
48. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
49. +-ATPase inhibitor pantoprazole
50. Pantoprazole does not interact with the pharmacokinetics of carbamazepine
51. Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults
52. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man
53. Lack of pharmacokinetic interaction between pantoprazole and diclofenac
54. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man
55. Pantoprazole does not influence the pharmacokinetics of ethanol in healthy volunteers
56. Effect of pantoprazole on ovulation suppression by a low-dose hormonal contraceptive
57. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers
58. Pantoprazole does not interact with nifedipine in man under steady-state conditions
59. Lack of pharmacokinetic and pharmacodynamic interaction of pantoprazole and phenprocoumon in man
60. No influence of pantoprazole on the pharmacokinetics of phenytoin
61. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man
62. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin
63. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole and pantoprazole
64. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease
65. Comparison of intravenous with oral pantoprazole in symptom relief and healing of reflux esophagitis
66. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole
67. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease
68. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen